[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-functional-disturbance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-functional-disturbance":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100360751","a-randomized-controlled-trial-of-thyroid-hormone-supplementation-in-hemodialysis-patients-100360751",false,"NCT03977207","A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients","THYROID-HD","Inclusion Criteria:\n\n* Age 18-75 years old\n* Received hemodialysis at least four weeks\n* Have two consecutive thyrotropin (TSH) levels \\>3.0-10.0mIU\u002FL during the screening period\n* Have normal free thyroxine (FT4) levels\n* Have ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active treatment with thyroid hormone supplementation or anti-thyroid medications\n* Active receipt of dialysis\n* Prior kidney transplantation\n* Life expectancy less than six months\n* Active malignancy or prior thyroid malignancy\n* Active pregnancy or planning a pregnancy\n* Active coronary ischemia or atrial fibrillation (evaluated by EKG)\n* Active congestive heart failure exacerbation\n* Osteoporosis\n* Weight in excess of 450 lbs.\n* Hyperthyroidism as determined by TSH \\\u003C0.5mIU\u002FL during the screening period, anti-thyroid medication use, or hyperthyroidism diagnosis","ALL","18 Years","75 Years",{"count":20,"type":21},336,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hypothyroidism, defined by elevated thyrotropin (TSH) levels, is a common endocrine complication in chronic kidney disease patients, and prior evidence shows that higher TSH levels, even within the normal laboratory range, are strongly associated with impaired quality of life and cardiovascular disease in this population. Levothyroxine is one of the most frequently prescribed medications in chronic kidney disease, yet its efficacy and safety in these patients have not been well-studied. Hence, this study will investigate 1) whether levothyroxine improves patient-centered (e.g., health-related quality of life, physical performance, strength) and 2) cardiovascular (e.g., coronary artery calcification, endothelial function, systolic function) outcomes in dialysis patients, and 3) if thyroid hormone replacement exerts classic metabolic effects (i.e., changes in body fat and resting energy expenditure) in this population.",[27,28,29],"Thyroid; Functional Disturbance","Hypothyroidism","Hemodialysis","RECRUITING","2025-08-30",{"date":33,"type":34},"2025-09-08","ACTUAL",{"date":36,"type":34},"2020-07-20",{"date":38,"type":21},"2025-11-30",{"name":40,"class":41},"University of California, Irvine","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100527947","eltroxin-administration-to-patients-with-extremely-low-t4-values-in-the-intensive-care-unit-100527947","NCT06154382","Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit","Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit: Comparison Between Groups and Therapeutic Outcomes","Inclusion Criteria: All patients aged 18--99 who were admitted to the general intensive care unit from January 2016 to November 22, 2023 for any reason, and who during their hospitalization in the intensive care unit had lower than normal T4 levels measured. It is about 350 patients. Of these, we will specifically examine the group of patients for whom an extremely low level of T4 was measured (less than 50% of the lower limit of the norm).\n\n\\-\n\nExclusion Criteria: Patients who were known to have a chronic thyroid dysfunction prior to their hospitalization in the unit, patients who were regularly treated with eltroxin prior to their hospitalization\n\n\\-","99 Years",{"count":52,"type":21},350,"OBSERVATIONAL","Nonthyroidal illness (formerly called sick euthyroid syndrome) is a common condition in patients hospitalized in the intensive care unit, and it is caused by changes in the levels of thyroid hormones in the blood . These changes are correlated to the severity of the critical illness, morbidity and mortality. This condition is characterized by low serum T3 levels, high rT3 levels, normal or low T4 levels, and normal or low TSH levels. Previous studies have shown a relationship between NTIS (nonthyroidal illness) and poor therapeutic outcomes in patients admitted with sepsis, multi trauma, ARDS, acute respiratory failure, septic shock and mechanically ventilated patients in intensive care .\n\nIn general, the recommendation is not to routinely take blood tests to evaluate thyroid function in critical patients in the intensive care unit, unless they were previously known to have a thyroid disease or there is a clinical suspicion that such a disorder developed during hospitalization in the intensive care unit. Also, studies so far have not shown an advantage for eltroxin administration to intensive care patients with low T3 and\u002For T4 levels when the laboratory tests indicate NTIS. However, there is a specific group of patients, with NTIS and extremely low T4 levels (less than 50% of the lower limit of the normal range) who have a particularly high mortality rate in intensive care (over 85%) and in whom it has not been investigated whether the administration of eltroxin will improve the therapeutic outcomes ( , i.e. was such a low T4 level in them considered a marker for the severity of their general critical illness, or is it another disorder in itself, the treatment of which would benefit the patient) . We would like to examine whether the administration of eltroxin in this specific group of patients, which has not been studied so far, will be beneficial in improving the therapeutic outcomes",[27],"2025-05-07",{"date":58,"type":34},"2025-05-11",{"date":60,"type":34},"2024-06-01",{"date":62,"type":21},"2026-02-01",{"name":64,"class":41},"Meir Medical Center"]